The COVID-19 pandemic showed the world that when it comes to pharmaceuticals, fast is achievable. Traditional models for drug development, manufacture, approval, and launch were upended. Timelines were shrunk and processes streamlined; existing drugs were repurposed, and the launch of novel ones accelerated. Bold new approaches led to countless lives being saved. Now, drug researchers and developers, manufacturers, and raw material suppliers are applying lessons learned to accelerating the future of pharma. This radical rethink will not only support future pandemic preparedness, but it will also revolutionize how pharmaceuticals targeting other diseases are developed and manufactured.